Programmed death protein 1 (PD1) is a common immunosuppressive member on the
surface of T cells and plays an imperative part in downregulating the immune system and …

Abstract Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4
(CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 …

Melanoma, a skin cancer associated with high mortality rates, is highly radio-and
chemotherapy resistant but can also be very immunogenic. These circumstances have led to …

Several cancers are highly refractory to conventional chemotherapy. The survival of tumors
in several cases is assisted by checkpoint immunomodulation to maintain the imbalance …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …

The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …

This study identifies mechanisms mediating responses to immune checkpoint inhibitors
using mouse models of triple-negative breast cancer. By creating new mammary tumor …

Background Programmed cell death protein-1 (PD-1) blockade therapies have
demonstrated durable responses and prolonged survival in a variety of malignancies …

Cancer is one of the most deadly diseases in the modern world. The last decade has
witnessed dramatic advances in cancer treatment through immunotherapy. One extremely …

Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …